DRW

APR 9 4 MM H

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Group Art Unit:

Unknown

WOLFGANG DÖRING ET AL.

Examiner:

Unknown

Serial No.:

10/595,067

Filed:

January 27, 2006

For:

METHOD FOR THE PRODUCTION OF OH-PROTECTED

[4-(2,6-DIAMINO-9H-PURIN-9-YL)-1,3-DIOXOLAN-2-

YL]METHANOL DERIVATIVES

Attorney Docket No.: WAS 0757 PUSA

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents U.S. Patent & Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97-1.98, the references listed and identified on the attached Forms PTO/SB08A and/or SB08B are being submitted herewith for consideration by the Examiner. This statement is being filed in accordance with 37 C.F.R. § 1.97(b).

While this Statement is being filed in compliance with the duty of disclosure, citation of the listed references is not to be construed as an admission that any of the references are "material" as defined under 37 C.F.R. § 1.56(b).

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8 (FIRST CLASS MAIL)

I hereby certify that this paper, including all enclosures referred to herein, is being deposited with the United States Postal Service as first-class mail, postage pre-paid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, U.S. Patent & Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit

William G. Conger
Name of Person Signing

Signature

S/N: 10/595,067 Atty Dkt No. WAS 0757 PUSA

Accompanying the Information Disclosure Statement is the statement of Dr. Robert Fränkel describing the content of the references cited in the Information Disclosure Statement.

No copies of the listed U.S. patent references or the listed U.S. patent application publication references have been included herewith pursuant to 37 C.F.R. § 1.98(a)(2). All other references have been provided as required. Consideration and entry into the record of the listed references is respectfully requested.

Respectfully submitted,

WOLFGANG DORING ET AL.

By: William (

William G. Conger Reg. No. 31,209

Attorney/Agent for Applicant

Date: <u>April 18,</u> 2006

BROOKS KUSHMAN P.C.

1000 Town Center, 22nd Floor Southfield, MI 48075-1238

Phone: 248-358-4400 Fax: 248-358-3351

PTO/SB/08A (10-96) [MODIFIED]

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

2

Complete if Known

Application Number Wolfgang Doering et al.

Filing Date January 27, 2006

First Named Inventor WOLFGANG DÖRING ET AL.

Group Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number WAS 0757 PUSA

(use as many sheets as necessary)

Sheet 1 of

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite	U.S. PATENT DOCUMENT Kind Code ² Number - (if known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
miliais	NO.	Number 2	(II KHOWII)	Applicant of Cited Document	MM-DD-YYYY	Passages of Relevant Figures Appear	
\vdash				· · · · · · · · · · · · · · · · · · ·			
							
 	-						

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (<i>if known</i>)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		EP	1 258 486 A2		Eli Lilly & Co.	11/20/2002		
		WO	01/58894 A1		Biochem Pharma	8/16/2001		
		WO	92/14729 A1		Emory University	9/03/1992		
		WO	97/21706 A1		Biochem Pharma	6/19/1997		
			_					
					_			

Examiner	•	Date	
Signature		Considered	
*EVALUATED.	Initial if reference considered whether as not station in in confe-	MDED COO Descrip	! Ab

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known				
				Application Number	10/595,067			
				Filing Date	January 27, 2006			
SIAII	INIENI BY	AP	PLICANT	First Named Inventor	WOLFGANG DÖRING ET AL.			
				Group Art Unit	Unknown			
(use as many sheets as necessary)				Examiner Name	Unknown			
Sheet	2	of	2	Attorney Docket Number	WAS 0757 PUSA			
	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		(2	Kim et al., "1,3-Dioxolanylpurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes," J. Med. Chem., Vol. 36, 1993, pp. 30-37					
		Νυ		ergent Asymmetric Syr es," Tetrahedron: Assym -2322				
		Nu Sy	Kim et al., "L- β -(2S,4S)- and L- α -(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships," Journal of Medicinal Chemistry, Vol. 36, No. 5, March 1993, pp. 519-528					
			Vobrüggen et al., "On the Mechanism of Nucleoside Synthesis," CHEM. BER. 114, 1981, pp. 1256-1268					
			March et al., "Advanced Organic Chemistry," Wiley & Sons, Inc., 3 rd Edition, p. 179 and pp. 310-317					
		1,	Greene et al., "Protection for the Hydroxyl Group Including 1,2- and 1,3-Diols," PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, Inc., 2 nd Edition, pp. 10-117					
		"E Sy	Protection for the NTHESIS, John Wile	e Amino Group," Protec y & Sons, Inc., 2 nd E	CTIVE GROUPS IN ORGANIC dition, pp. 309-385			

Examiner	Date	
Signature	Considered	- 1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

WOLFGANG DÖRING ET AL.

Serial Number

Group Art Unit:

Filed:

For:

METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES

Information Disclosure Statement

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir or Madam:

I, Robert Fränkel, associated with the preparation and prosecution of the above-identified application, residing at Krottenkopfstr. 8, 81377 München, Germany, wish to call the attention of the Patent Examiner to the references enumerated on the enclosed PTO Form-1449.

I believe the documents enumerated on the enclosed Form PTO-1449 and attached thereto, are cited in the enclosed International Search Report as well was in the application and may be material to the examination of the application.

Therefore, it is respectfully requested that the foregoing Information Disclosure Statement be considered by the Examiner and incorporated into the file of this application.

I wish to comment as follows concerning the prior art references enumerated on PTO Form-1449:

EP 1 258 486 A2, cited in the International Search Report, is already in English language.

WO 01/58894 A1, cited in the International Search Report, is already in English language.

WO 92/14729 A1, cited in the application, is already in English language.

WO 97/21706 A1, cited in the application, is already in English language.

KIM ET AL.: "L- β -(2S,4S)- and L- α -(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships", Journal of Medicinal Chemistry, Vol. 36, No. 5, March 1993, Pages 519 – 528, cited in the International Search Report, is already in English language.

KIM ET AL.: "1,3-Dioxolanylpurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes", Journal of Medicinal Chemistry, Vol. 36, No. 5, March 1993, Pages 30 – 37, cited in the International Search Report, is already in English language.

EVANS ET AL.: "Divergent Asymmetric Syntheses of Dioxolane Nucleoside Analogues", Tetrahedron: Asymmetry, Vol. 4, No. 11, 1993, Pages 2319 – 2322, cited in the International Search Report, is already in English language.

GREENE ET AL., WUTS ET AL.: "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 2nd Edition, Pages 10 – 117 and Pages 309 – 385, cited in the application, is already in English language.

VORBRÜGGEN ET AL., HOEFLE ET AL.: "On the Mechanism of Nucleoside Sysnthesis", Chem. Ber. 114, 1981, Pages 1256 – 1268, cited in the application, is already in English language.

MARCH ET AL.: "Advanced Organic Chemistry", Wiley & Sons, Inc., 3rd Edition, Page 179 and Pages 310 – 312, cited in the application, is already in English language.

Signed this Ob day of February, 2006.

Dr. Robert Fränkel